Midecamycin is a macrolide antibiotic. Macropen is usually active against the following organisms: Staphylococcus spp, Streptococcus spp, Mycoplasma pneumoniae, Corynebacterium diphtheriae, Listeria monocytogenes, Neisseria gonorrhoeae, Bordetella pertussis, Legionella pneumophila, Ureaplasma urealyticum, Chlamydia trachomatis, Haemophilus influenzae. It acts by inhibition of protein synthesis by binding 50 S ribosomal subunits of susceptible organisms.

Midecamycin is contraindicated in patients with hypersensitivity to this antibiotic.

Antibiotic with a broad spectrum effect. It is a drug used against such bacteria: Streptococcus pyogenes, Streptococcus pneumoniae, Mycoplasma, Treponema pallidum, Borditella pertussis, Chlamydia and others.

Midecamycin is indicated for the treatment of the following infections: Infections of the respiratory and urinary tract, Skin and soft tissue infections, Diphtheria, scarlet fever and pertussis.

It is absorbed well and allocate in tissues and output from the body through bile.

Prescribed for O.R.L infection, complication in the respiratory tract, whooping cough, syphilis, stomach ulcers with Helicobacter pylori.

Midecamycin delayed Cyclosporine and Warfarin excretion, the hepatic inactivation of the ergot alkaloids and Carbamazepine are decreased.

Adult’s dosage is 400 mg three times a day.

Children daily dose is 30-50 mg / kg in 2 divided doses, and for the heavy infections in the three receptions before meal.

Renal and haematological systems should be monitored during prolonged high dose therapy.

The most frequent side effects of Midecamycin preparations are: anorexia, nausea, vomiting, diarrhea, skin allergies disease.

Macropen also increase the hepatic transaminases and the concentration of bilirubin in the blood.